Endovascular Removal of Thrombus and Right Heart Masses Using the AngioVac System: Results of 234 Patients from the Prospective, Multicenter Registry of AngioVac Procedures in Detail (RAPID)

Moriarty, John M.; Rueda, V.; Liao, Millie; Kim, Hyun J; Rochon, Paul J.; Zayed, Mohamed A.; Lasorda, David; Golowa, Y.; Shavelle, David M.; Dexter, David J.

doi:10.1016/j.jvir.2020.09.012

Cited by 50 publications

(44 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, a large registry with 234 concomitant procedures demonstrated the safety of the AngioVac System, with only 3 procedure-related deaths. The indication for the procedure was a right heart mass in 52.6% of cases; intraprocedural success, defined as >70% mass removal, was achieved in nearly 60% of patients with right heart masses [ 13 ]. Our own results coincide with previously published data, as seen in Table 4 , demonstrating good intraoperative success [ 5 , 7 , 14 – 16 ].…”

Section: Discussionmentioning

confidence: 99%

Endovascular Treatment of Right Heart Masses Utilizing the AngioVac System: A 6-Year Single-Center Observational Study

Katapadi

Richards

Fischer

et al. 2021

Journal of Interventional Cardiology

View full text Add to dashboard Cite

Objective. To describe our institution’s experience with the AngioVac system. Background. Intracardiac and intravascular masses previously required surgical excision, but now, there are a number of minimally invasive options. With the advent of vacuum aspiration, more specifically the AngioVac System (AngioDynamics, NY, USA), there exists a system with both low mortality and minor complications. However, the number of retrospective studies remains limited. Outcome data for high-risk patients are also limited. Methods. Data were collected and analyzed in patients who underwent AngioVac therapy at our tertiary care center from January 2014 to December 2020. Results. Our results demonstrated a 93.3% intraoperative success rate and a 100% intraoperative survival rate. However, a number of complications, including but not limited to hematomas, anemia, and hypotension, occurred, as described below. Conclusions. Our experiences demonstrated good outcomes and continue to support the usefulness of the AngioVac System. The data also support the use of AngioVac as a treatment option for the debulking or removal of right heart masses in critically ill patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Endovascular Treatment of Right Heart Masses Utilizing the AngioVac System: A 6-Year Single-Center Observational Study

Katapadi

Richards

Fischer

et al. 2021

Journal of Interventional Cardiology

View full text Add to dashboard Cite

show abstract

“…Percutaneous access was achieved in all cases and technical success, defined as > 70% mass resection, was achieved in 61% of patients. 6 There was no statistically significant difference in technical success between the oncology and non-oncology groups. Size was not a statistically significant predictor of success.…”

Section: Discussionmentioning

confidence: 82%

“…5 Technical success was defined as > 70% thrombus aspiration, in keeping with previous publications, as estimated based on pre and postintervention echocardiography. 6 Secondary endpoints included comparative technical and thrombus-related factors. Thrombi were evaluated by an independent TEE reader pre and postoperatively for size and mobility, categorized as mobile or adherent .…”

Section: Study Endpointsmentioning

confidence: 99%

AngioVac Aspiration Thrombectomy of Right Atrial Thrombus is Safe and Effective in Cancer Patients

Callese

O’Brien

Wilhalme

et al. 2021

Annals of Vascular Surgery

Self Cite

View full text Add to dashboard Cite

“…A prospective registry found the AngioVac System (Angiodynamics, Inc., Queensbury, NY, USA) to frequently enable aspiration of bulky thrombi in the inferior vena cava (IVC) or right heart through a large sheath after creation of a venous-venous bypass circuit. 24 Endovascular thrombolysis methods have not been compared head-to-head in large, well-designed studies. In one pilot randomized trial, 48 patients with acute iliofemoral DVT received CDT using an ultrasound drug delivery catheter (EkoWave; Boston Scientific Corp.).…”

Section: New Insights Into the Clinical Effectiveness Of Cdt And Related Therapiesmentioning

confidence: 99%

Catheter-directed thrombolysis for deep vein thrombosis: 2021 update

Goldhaber

Magnuson²,

Chinnakondepalli³

et al. 2021

Vasc Med

View full text Add to dashboard Cite

Catheter-directed thrombolysis (CDT) has been utilized as an adjunct to anticoagulant therapy in selected patients with deep vein thrombosis (DVT) for approximately 30 years. CDT used to be limited to patients with DVT causing acute limb threat and those exhibiting failure of initial anticoagulation, but has expanded over time. Randomized trials evaluating the first-line use of CDT for proximal DVT have demonstrated that CDT does not produce a major reduction in the occurrence of post-thrombotic syndrome (PTS) and that it is poorly suited for elderly patients and those with limited thrombus extent or major risk factors for bleeding. However, CDT does offer selected patients with acute iliofemoral DVT improvement in reducing early DVT symptoms, in achieving reduction in PTS severity, and in producing an improvement in health-related quality of life (QOL). Clinical practice guidelines from medical and surgical societies are now largely aligned with the randomized trial results. This review offers the reader an update on the results of recently completed clinical trials, and additional guidance on appropriate selection of patients with DVT for catheter-directed thrombolytic therapy.

show abstract

Endovascular Removal of Thrombus and Right Heart Masses Using the AngioVac System: Results of 234 Patients from the Prospective, Multicenter Registry of AngioVac Procedures in Detail (RAPID)

Cited by 50 publications

References 23 publications

Endovascular Treatment of Right Heart Masses Utilizing the AngioVac System: A 6-Year Single-Center Observational Study

Endovascular Treatment of Right Heart Masses Utilizing the AngioVac System: A 6-Year Single-Center Observational Study

AngioVac Aspiration Thrombectomy of Right Atrial Thrombus is Safe and Effective in Cancer Patients

Catheter-directed thrombolysis for deep vein thrombosis: 2021 update

Contact Info

Product

Resources

About